Servier Pharmaceuticals highlighted ongoing clinical trials and multidisciplinary care models at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia, Pennsylvania.
Running from November 12 to 15, the conference focused on the theme “Crossing the Translational Divide: From Neurons to Novel Therapies.” As documented by Oncodaily – Oncology News, Insights, Stories, presentations at the event highlighted the Phase 3 ACTION study of dordaviprone alongside a newly launched Phase 2 trial of JZP3507 for recurrent meningioma.
Researchers also presented findings from the GLIX1 Phase 1/2a research in high-grade glioma. The program’s diverse sessions covered glioma biology, targeted therapies, immunotherapy, cancer neuroscience, clinical-trial design, brain metastases, neuroimaging, neuropathology, pediatric and rare tumors, radiation, neurosurgery, survivorship, and health disparities.
Founded by Jacques Servier and now governed by a non-profit foundation, Servier Pharmaceuticals is an international pharmaceutical company headquartered in France. The company invests nearly 25% of its turnover in research and development, employing 3,000 researchers among its 22,000 staff worldwide. In 2018, Servier acquired Shire’s oncology branch in Boston and opened its new U.S. headquarters in 2019, expanding its presence in neuro-oncology research.
- Targeted Trials: Recent presentations highlighted ongoing studies evaluating specific therapies, such as the Phase 3 ACTION trial for dordaviprone and Phase 2 testing for JZP3507.
- Early-Phase Research: Early-stage data, including GLIX1 Phase 1/2a results in high-grade glioma, continue to inform neuro-oncology pipelines.
- Multidisciplinary Focus: Conference sessions emphasized connecting basic neuroscience with clinical applications to address central nervous system tumors.
During the meeting, the Society for Neuro-Oncology announced a $75,000 early-career NF1 outcomes-research grant. The award aims to support investigators studying neurofibromatosis type 1 outcomes, reflecting a broader commitment to supporting the next generation of specialists in the field.
| Trial / Study | Phase | Indication |
|---|---|---|
| ACTION Trial (dordaviprone) | Phase 3 | Specified Neuro-Oncology Indications |
| JZP3507 Study | Phase 2 | Recurrent Meningioma |
| GLIX1 Research | Phase 1/2a | High-Grade Glioma |
- Society for Neuro-Oncology (SNO). 31st Annual Meeting Program and Abstracts. Philadelphia, Pennsylvania.
- Oncodaily – Oncology News, Insights, Stories.